Search | Clinical Trials Finder

Conditions: Diabetic Macular Edema
Interventions: Fluocinolone Acetonide, Standard of care laser photocoagulation; Drug · Procedure
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Asthma (Diagnosis)
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Los Angeles, California • San Jose, California • Melbourne, Florida + 18 more

Conditions: Nerve Block; Pain Medication
Interventions: Oburator Nerve block, Sham Injection in pectineus muscle.; Procedure
Lead sponsor: Trinity Health Of New England; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Alzheimer's Disease
Interventions: CERE-110: Adeno-Associated Virus injection Surgery, Placebo Surgery; Drug · Procedure
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more

Conditions: Diabetic Macular Edema
Interventions: Faricimab, Sham Procedure; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 119
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 105 more

Conditions: Pain, Amputation
Interventions: 10 mL 2% lidocaine, 10 mL preservative free saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Thyroid Eye Disease (TED)
Interventions: VV-14305, Sham (No Treatment); Genetic · Other
Lead sponsor: Kriya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Livonia, Michigan • Las Vegas, Nevada • Erie, Pennsylvania

Conditions: Neovascular Age-related Macular Degeneration
Interventions: 2.0 mg OPT-302, 2.0 aflibercept, Sham; Biological · Procedure
Lead sponsor: Opthea Limited; Industry
Eligibility: 50 Years and older
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 60
States / cities: Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more

Conditions: Vitreomacular Adhesion Including Macular Hole
Interventions: Ocriplasmin, Sham injection; Drug · Other
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 22 more

Conditions: Macular Degeneration
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 50 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Knee Osteoarthritis
Interventions: Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection; Procedure
Lead sponsor: Center For Interventional Pain and Spine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Exton, Pennsylvania

Conditions: Geographic Atrophy
Interventions: APL-2, Sham Procedure; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 73
States / cities: Phoenix, Arizona • Arcadia, California • Bakersfield, California + 61 more

Conditions: Pain, Postoperative
Interventions: Local anesthesia at incision site, Sham QL, Sham Local, QL; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions: 4mg CLS-TA Suprachoriodal Injection, Sham Procedure; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Leber Hereditary Optic Neuropathy
Interventions: GS010, Sham Intravitreal Injection; Genetic · Other
Lead sponsor: GenSight Biologics; Industry
Eligibility: 15 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Pasadena, California • Atlanta, Georgia • Philadelphia, Pennsylvania

Conditions: Exudative Age-related Macular Degeneration
Interventions: RBM-007 Injectable Solution, Aflibercept, Sham; Drug
Lead sponsor: Ribomic USA Inc; Industry
Eligibility: 55 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more

Conditions: Age-Related Macular Degeneration
Interventions: E10030, bevacizumab or aflibercept, E10030 sham injection; Drug
Lead sponsor: Ophthotech Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 100
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more

Conditions: Macular Edema, Diabetic
Interventions: Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more

Conditions: Pain Due to Intrauterine Contraceptive Device
Interventions: Paracervical Block (PCB), No Paracervical Block (Sham PCB); Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Diego, California

Conditions: Dental Anesthesia, Anesthesia, Local, Anesthesia, Reversal
Interventions: OraVerse, Sham injection; Drug · Other
Lead sponsor: Novocol Pharmaceutical of Canada, Inc.; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: San Francisco, California • Indianapolis, Indiana • Columbus, Ohio + 4 more

Conditions: Angelman Syndrome
Interventions: GTX-102, Sham-LP; Drug · Procedure
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: COVID-19-Induced Parosmia
Interventions: Stellate Ganglion Block, Placebo Sham Injection; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

Obturator Nerve Block With Femoral and Sciatic Block

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Sciatic Block in Contralateral Limb Phantom and Residual Limb Pain

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

RESCUE and REVERSE Long-term Follow-up

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Pain Control for Intrauterine Device Placement Using Paracervical Block

Study of OraVerse® for Safety and Efficacy in Pediatric Dental Patients

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

Stellate Ganglion Block for COVID-induced Parosmia